Clinical trials: SGLT2-Inhibitors
Diabetes Mellitus, Cellular Senescence
Effect of Sodium-glucose Cotransporter-2 Inhibitor in Cellular Senescence in Patients With Cardiovascular Diseases or Type 2 Diabetes
Patients with type 2 diabetes (T2D) are more prevalent with aging-related comorbidities and frailty, which leads to a shorter life expectancy than non-diabetic individuals and that this excess mortality is largely attributable to…
- Conditions
- Diabetes Mellitus, Cellular Senescence, Sodium-Glucose Transporter 2 Inhibitors
- Trial name
- NCT05975528
- Testing
- SGLT2 inhibitor, Glimepiride
- Where
- South Korea
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Myocardial Infarction, Diabetes Mellitus, Type 2
Evaluation of the Effect of SGLT-2 Inhibitors on Cardiac Remodeling in Post Myocardial Infarction Patients
A prospective, randomized, controlled study will be conducted at Clinical Cardioglogy department, Ain Shams University Hospitals, assessing the efficacy and tolerability of SGLT2 inhibitors (dapagliflozin) addition on the…
- Conditions
- Myocardial Infarction, Diabetes Mellitus, Type 2, Myocardial Remodeling, Ventricular
- Trial name
- NCT05335629
- Testing
- Dapagliflozin 10Mg Tab
- Where
- Egypt
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
SGLT-2 Inhibitors, Advanced Glycation End Products
The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End Products
Single-center open-label multiple dose randomized two period cross-over study to examine Advanced Glycation End Product (AGE) levels in human subjects pre and post empagliflozin administration.
- Conditions
- SGLT-2 Inhibitors, Advanced Glycation End Products, Diabetes
- Trial name
- NCT02768220
- Testing
- empagliflozin, linagliptin
- Volunteers
- healthy volunteers welcome
- Sponsor
- Northwell Health
Diabetic Ketoacidosis, Postoperative Care
Postoperative Euglycemic Ketoacidosis Frequency in Sodium-Glucose Cotransporter-2 Inhibitor Users
The goal of this observational study is to determine the frequency of postoperative euglycemic diabetic ketoacidosis (EDKA) in patients receiving Sodium- Glucose Cotransporter-2 (SGLT-2) inhibitors.
- Trial name
- SGLT-2I (NCT07127406)
- Where
- Turkey (Türkiye)
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Kocaeli City Hospital
Diabetes Mellitus, Type 2
A Study to Determine Acute (After First Dose) and Chronic (After 28 Days) Effects of Empagliflozin (BI 10773) on Pre and Postprandial Glucose Homeostasis in Patients With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus and Healthy Subjects
An open-label, phase II study to assess the acute and chronic effects of empagliflozin (BI 10773)on fasting and postprandial glucose homeostasis in patients with IGT and type 2 diabetes mellitus and assess the acute effects of…
- Trial name
- NCT01248364
- Testing
- BI 10773
- Where
- 3 sites in Austria, Germany and 1 more
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
SGLT2 Inhibitors, Lower Urinary Track Symptoms
SGLT-2 Inhibitors and Lower Urinary Tract Symptoms
This prospective observational study aims to evaluate the effects of sodium-glucose cotransporter 2 (SGLT-2) inhibitors on lower urinary tract symptoms (LUTS) in patients with type 2 diabetes mellitus.
- Conditions
- SGLT2 Inhibitors, Lower Urinary Track Symptoms, Overactive Bladder
- Trial name
- NCT07716774
- Testing
- No Intervention: Observational Cohort
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Marmara University
Renal Insufficiency, Chronic, Cardiac Catheterization
Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients
This study aim to investigate the protected effects of short-term use of dapagliflozin (administered within 3 days after procedure) in CKD patients after coronary angiography or percutaneous coronary intervention, as well as…
- Conditions
- Renal Insufficiency, Chronic, Cardiac Catheterization, Percutaneous Coronary Intervention
- Trial name
- NCT05225077
- Testing
- Dapagliflozin 10 MG [Farxiga]
- Where
- South Korea
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Dong-A University
Inappropriate ADH Syndrome
Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study
Empagliflozin (Jardiance)® is a sodium glucose co-transporter 2 (SGLT2)-Inhibitor, which is a new treatment option developed for patients with diabetes mellitus type 2.
- Trial name
- DIVE (NCT02729766)
- Testing
- Induced hypotonic hyponatremia - SIAD model, Empagliflozin 25mg Tbl
- Where
- Switzerland
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Breast Cancer
Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC
Background: Breast cancer is the most frequently diagnosed malignancy among women worldwide and a major cause of morbidity and mortality.
- Trial name
- SGLT2i/DPPi (NCT07436663)
- Testing
- Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy, Sitagliptin (DPP4 inhibitor), Standard Care (in control arm)
- Where
- Egypt
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Tanta University
Chronic Kidney Disease stage3
Effect of Empagliflozin on Urinary Excretion of Adenosine and Osteocyte Function in Patients With Chronic Kidney Disease
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are the newest class of orally drugs for the treatment of type 2 diabetes. These drugs decrease plasma glucose levels by inhibiting its reabsorption in the proximal tubules of the…
- Trial name
- NCT04961931
- Testing
- Empagliflozin 10 MG
- Where
- Poland
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Medical University of Lodz
Obesity
Weight Loss In Obese Subjects Taking Either GW869682 Or Placebo 3 Times Per Day For 12 Weeks
GW869682 causes glucose to be excreted in the urine. The purpose of this study is to see whether enough calories from glucose are excreted in the urine to cause weight loss.
- Trial name
- NCT00297180
- Testing
- GW869682
- Where
- 3 sites in United States
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Large Vessel Vasculitis, Giant Cell Arteritis (GCA)
Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)
Large vessel vasculitis (LVV) is a disease that causes damage to blood vessels. This damage to blood vessels can increase the risk of patients with LVV developing cardiovascular disease, including heart attacks and strokes.
- Conditions
- Large Vessel Vasculitis, Giant Cell Arteritis (GCA), Takayasu Arteritis
- Trial name
- DERAIL-LVV (NCT06887062)
- Testing
- Bosentan and dapagliflozin
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Type2diabetes
Effect of SGLT-2 Inhibitors in Patients With T2DM and Moderate to Severe Liver Fibrosis
This retrospective study will be of 12 months duration where 40 T2DM patients coming to FORTIS C-DOC hospital in OPD with F3 fibrosis will be included in the study.
- Trial name
- NCT05943899
- Where
- India
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Diabetes Foundation, India
Diabetes Mellitus, Gout
Pharmacogenetics of SGLT2 Inhibitors
Sodium-dependent glucose transporter-2 (SGLT2) inhibitors are a new class of anti-diabetic drugs, which increase urinary glucose excretion thereby promoting weight loss and decreasing plasma glucose levels.
- Conditions
- Diabetes Mellitus, Gout, Hyperuricemia
- Trial name
- SGLT2iPGx (NCT02462421)
- Testing
- Canagliflozin
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Diabetic Nephropathies, Kidney Diseases
Transformative Research in Diabetic Nephropathy 2.0
The goal of this observational study is to learn more about kidney health in adults with diabetic kidney disease and other groups. Researchers will study kidney tissue and other samples.
- Conditions
- Diabetic Nephropathies, Kidney Diseases, Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
- Trial name
- TRIDENT 2 (NCT07444203)
- Testing
- Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Renin-angiotensin-aldosterone system blockade, Glucagon-like peptide-1 receptor agonists (GLP 1 RA)
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Chronic Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF)
Precision Subtyping and Prognostic Study of Heart Failure Based on Multi-Omics Integration and Clinical Indicators: A Prospective Single-Center Cohort Study
This is a prospective single-center cohort study conducted at The First Affiliated Hospital of Xinjiang Medical University, aiming to enroll 400 patients with chronic heart failure (including HFrEF, HFmrEF, HFpEF) and 200 healthy…
- Conditions
- Chronic Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure With Preserved Ejection Fraction (HFPEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
- Trial name
- HF-MultiOmics (NCT07355088)
- Where
- China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Xinjiang Medical University
Diabetes After Total Pancreatectomy
Involvement of Dipeptidyl Peptidase-4 and Sodium-glucose Co-transporter-2 in Extrapancreatic Glucagon Secretion
Glucagon is a 29-amino acid peptide hormone of essential importance for glucose homeostasis. Hitherto glucagon has been believed to be secreted only from the pancreas, but recent studies show that glucagon is also secreted from…
- Trial name
- Px-Meal (NCT04061473)
- Testing
- Sitagliptin 100mg, Empagliflozin 25 MG
- Where
- Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Inflammation
Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Inflammation
The research aims to understand how a specific type of medication called Sodium-glucose co-transporter 2 (SGLT2) inhibitors affect cardiorenal inflammation.
- Trial name
- EFSII (NCT06812429)
- Testing
- Dapagliflozin (DAPA)
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Diabetic Foot Ulcer
SGLT-i Use in Diabetic Foot Ulcer Disease
Background: People with diabetes and either current or previous diabetic foot ulcer disease (DFUD) are at very high risk for adverse cardiovascular events including heart attacks and strokes.
- Trial name
- NCT06000722
- Testing
- eDelphi method
- Where
- United Kingdom
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Leicester
Type 2 Diabetes Mellitus
Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes Mellitus
The main pathogenesis of type 2 diabetes mellitus is insulin resistance and insufficient secretion of insulin by pancreatic beta cells.
- Trial name
- NCT04014192
- Testing
- Dapagliflozin, Empagliflozin, Canagliflozin
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital